Respidone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Respidone

What is Respidone? (Risperidone)

Property Description
Active ingredient Risperidone (INN)
Form Oral tablets, Oral solution, Injectable suspension
Pharmacological class Atypical Antipsychotic (SGA)
Common purpose Stabilization of mood and perception
Origin Synthetic benzisoxazole derivative

What Type of Medicine is Respidone?

Respidone is a prescription-only medicine (POM) whose active ingredient is Risperidone. It is formally classified as an Atypical Antipsychotic, belonging to the broader class of Second-generation antipsychotics (SGAs). This classification reflects the medicine's role in the specialized management of conditions characterized by disruptions in thought and perception. The drug is a synthetic compound that is a benzisoxazole derivative and functions as a psychotropic agent on the Central Nervous System (CNS). Being categorized as atypical differentiates it from older neuroleptics, largely due to its balanced action profile on multiple neurotransmitter systems.


Composition, Forms, and Origin

The product is a single active ingredient preparation, meaning it contains only the compound Risperidone. Respidone is uniquely characterized by its availability in specialized forms, including conventional oral tablets, a concentrated oral liquid solution, and orally disintegrating tablets. The medicine is utilized across these varied delivery mechanisms to meet different clinical requirements. Furthermore, the body’s metabolism of Risperidone produces an active compound known as 9-hydroxyrisperidone, or Paliperidone, which itself is an established analogue used in related therapeutic protocols. The long-acting injectable forms of Risperidone are clinically recognized for supporting long-term medication adherence.


General Purpose and Mechanism Principle

The general purpose of this medicine is to provide pharmacological stabilization and support for brain functions involved in regulating mood, thought, and perception. It primarily achieves this through its specific mechanism of effect as a dual-action agent: it antagonizes, or blocks, certain receptors for the brain's natural chemical messengers, specifically dopamine (D2) and serotonin (5-HT2A). This dual targeting profile is key to its atypical designation and allows the medicine to effectively help restore a more stable chemical balance in the brain's communication pathways.

Regulatory References

  1. Risperidone - StatPearls - NCBI Bookshelf - NIH
  2. RISPERIDONE tablet - DailyMed - NIH

What side effects are possible with Respidone?

Possible Side Effects and Safety Information

The official safety profile for Respidone (Risperidone) classifies possible adverse reactions based on their observed frequency in clinical studies and groups them by affected physiological system. The classification framework used is consistent with regulatory standards, separating the most common events from those that are rare but clinically serious.

Adverse Reaction Classifications

Classification Examples of Officially Listed Adverse Reactions
Very Common Headache, Insomnia (difficulty sleeping), Parkinsonism (a movement disorder)
Common Sedation or somnolence, Weight increased, Akathisia (inability to remain still), Dizziness, Hyperprolactinemia
Uncommon QT prolongation (a cardiac effect), Cerebrovascular events (e.g., stroke), Syncope (fainting)

Adverse effects are documented across several System-Organ Classes, notably Nervous System Disorders (including various movement symptoms), Metabolism and Nutrition Disorders (including significant weight gain and Hyperglycemia), and Vascular Disorders (including Orthostatic Hypotension).

Serious Safety Considerations

The regulatory label highlights serious reactions such as Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD), which involves involuntary, repetitive movements. Additionally, an increased risk of mortality and Cerebrovascular Adverse Events (CVAEs) has been observed in older adults with dementia-related psychosis, a population for which the medicine is not approved.

Safety Patterns and Restrictions

Some safety patterns relate to the timing of exposure; for example, Orthostatic Hypotension is reported more frequently at the start of treatment. The official documentation includes limitations requiring the frequent monitoring of metabolic parameters (e.g., blood glucose and weight) and attention to pre-existing conditions, particularly cardiovascular disease.

Overdose and Emergency Response

The official regulatory documentation describes the signs and manifestations of a Respidone (Risperidone) overdose. Documented presentations center on Central Nervous System (CNS) depression, which may include drowsiness, sedation, or potentially coma. Other neurological signs documented are seizures and involuntary muscle movements classified as Extrapyramidal Symptoms (EPS).

The official profile highlights serious cardiovascular instability, including tachycardia (fast heart rate) and hypotension (low blood pressure). Of critical concern is the documented risk of QTc prolongation, which may lead to ventricular arrhythmia and is considered a severe, life-threatening outcome. For these reasons, continuous Electrocardiogram (ECG) monitoring and close medical supervision are required in documented cases of overdose.

Immediate medical attention must be sought for any suspected overdose. Regulatory guidance explicitly mandates that individuals immediately call emergency services if there is collapse, a seizure, signs of respiratory depression (trouble breathing), or an inability to be awakened. The official management strategy is primarily symptomatic and supportive, as no specific antidote is known. There is a noted caution regarding pediatric toxicity and increased risk for patients with renal or hepatic impairment.

Therapeutic Uses of Respidone

What Respidone Treats: Main Uses and Benefits

Respidone (Risperidone) is a psychotropic agent generally considered relevant for easing symptoms associated with complex mental health conditions. It is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on disruptions in thought, mood, and behavior. The medication is commonly used for conditions including Schizophrenia, manic or mixed episodes of Bipolar I Disorder, and severe, persistent irritability associated with Autism Spectrum Disorder.


Stabilization of Disrupted Thought and Perception

This medication is commonly applied in the symptomatic management of Schizophrenia, addressing symptom clusters that may become intense or disruptive, such as hallucinations and delusions. It assists with preserving functional stability and may assist with promoting clearer thinking during acute and chronic phases of the condition.

“Respidone supports the patient by providing supportive relief when symptoms interfere with routine activities.”

Management of Acute Mood and Behavioral Shifts

Respidone is applicable within clinical settings that involve acute or disruptive symptom patterns. It plays a role in managing symptoms of heightened physiological activity—like the extreme mood and energy shifts seen in Bipolar I Disorder—and also in addressing severe behavioral dysregulation (aggression and self-injury) in specific pediatric and elderly patients. It contributes to easing discomfort and supports the patient during difficult episodes by easing distress.


Quick Fact: Supports Management of Psychotic Symptoms

This medication is relevant for easing symptoms related to systemic imbalance in conditions characterized by periods of heightened symptoms, offering support in the management of thought and perception disturbances.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Population Eligibility and Restrictions


The eligibility profile for Respidone (Risperidone) is strictly defined by regulatory authorities to classify who can and cannot use the medicine, based on established use, contraindications, and conditional status.

Contraindications and Non-Eligibility

Respidone is contraindicated in patients with known hypersensitivity to the active ingredient, risperidone, or any related components. Use is also not approved for elderly patients with dementia-related psychosis, as official warnings note an increased risk of death in this population.

Established and Conditional Use

Use is formally established for adults across all labeled indications. Pediatric eligibility is restricted by specific age thresholds: Schizophrenia is established for ages 13 and older, Bipolar Mania for ages 10 and older, and irritability associated with Autistic Disorder for children aged 5 and older. Use is not established for populations below these age cutoffs.

Special Population Restrictions

Specific patient conditions require conditional use. Individuals with severe hepatic or renal impairment are subject to restrictions due to altered drug elimination and metabolism. Additionally, use during the third trimester of pregnancy is conditional due to the risk of extrapyramidal and/or withdrawal symptoms in the neonate. For nursing mothers, the medicine is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents that co-administration of Respidone (Risperidone) with certain other substances may result in pharmacokinetic or pharmacodynamic interactions.

Pharmacokinetic Interactions

Interacting Agents Official Outcome Regulatory Context
CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine) Increases the plasma concentration of Risperidone and the total active antipsychotic fraction. Dose adjustment may be required upon initiation or discontinuation.
CYP3A4/P-gp Inducers (e.g., Carbamazepine) Decreases the plasma concentration of the total active antipsychotic fraction. Requires specific regulatory caution due to altered exposure.
Cimetidine and Ranitidine Increases the bioavailability of Risperidone. Officially documented effect on drug levels.

Pharmacodynamic Interactions and Restrictions

Co-administration with other centrally-acting drugs or alcohol is officially documented to carry a risk of additive CNS depressant effects (e.g., sedation). Combining the drug with hypotensive agents may enhance the risk of orthostatic hypotension due to Risperidone's alpha-blocking activity. Risperidone may antagonize the effects of levodopa and other dopamine agonists. Elderly patients with dementia-related psychosis represent a population where the combination is contraindicated due to an officially documented increased risk of mortality. The regulatory profile also notes that the clearance of the active moiety is officially decreased in patients with severe renal or hepatic impairment.

Mechanism of Action

Dual Regulation of Dopamine and Serotonin Signaling

Respidone exerts its primary pharmacodynamic action by acting as an antagonist (blocker) at specific central nervous system targets, including the Dopamine D2 receptor and the Serotonin 5 -HT2 A receptor. The interaction at these sites results in a reduction of dopamine-mediated signaling and an alteration of serotonin activity in pathways relevant to cognitive and affective processing. Simultaneous antagonism of both D2 and 5 -HT2 A receptors affects multiple neurotransmitter systems. This distinct modulation of signaling dynamics contributes to the stabilization of neural communication in specific brain pathways.


Secondary Influence on Adrenergic and Histamine Systems

The drug also interacts with and blocks Alpha-1 (alpha1) adrenergic receptors and Histamine ( H1) receptors. This secondary action modulates noradrenergic and histaminergic systems, which govern levels of central nervous system excitation. The consequence of these off-target interactions is characterized by decreased signaling within CNS arousal pathways and modulation of peripheral vascular reflexes.

Dosage and Administration Information

Respidone follows specific administration and dosing protocols. The medicine is available for oral administration as conventional tablets, an oral solution, and orally disintegrating tablets (ODT), and also as long-acting injectable suspensions for deep intramuscular (IM) or subcutaneous (SC) use. Oral forms can generally be taken with or without food; the oral solution may be diluted in compatible non-alcoholic liquids, such as water or coffee, but not tea or cola.

Use of the medicine typically begins with a low initial dose that is then gradually increased, a process known as titration, to reach the defined maintenance dose range. For adults with Schizophrenia, the oral dosage is often titrated to a range of 4 mg to 8 mg daily. Oral forms are generally taken once or twice daily, whereas the long-acting injectable forms are administered less frequently, on a schedule of either every two weeks or once monthly, depending on the specific formulation.

Specific dosing adjustments are utilized for certain populations. Older adults and patients with severe renal or hepatic impairment are typically initiated on a lower starting dose (e.g., 0.5 mg twice daily) with slower titration. Additionally, when initiating one type of long-acting injection, oral Respidone is administered concurrently for the first three weeks to ensure continuous presence of the medicine while the injectable form reaches therapeutic concentrations.

Recent Clinical Evidence

Respidone: Recent Clinical Evidence

Evidence for Pain Management

Initial Phase 2 studies focused on the research goals of dose-finding and characterizing short-term side effects.

Clinical Trial Outcomes

In a 12-week Phase 3 trial, the primary endpoint analysis involved measuring differences in mean pain scores between the intervention and placebo groups. The treatment effect was evaluated across various patient subgroups in exploratory analyses.

A post-hoc analysis focused on early changes in pain scores following administration.

Combination Therapy Studies

Studies have evaluated the combination of the two ingredients to measure parameters related to nerve function and chronic inflammation. Findings from this exploratory research are considered limited by investigators, and further investigation is required to draw firm conclusions regarding mechanism.

Safety and Patient Populations

Research on safety has primarily included adult participants. Further study is required to fully characterize the effects in patients with severe kidney impairment. The research protocol included safety analysis for characterizing the observed profile and reporting the frequency of adverse events. Initial studies examined the effects of the lowest available dose.

Conclusion Summary

Current research has focused on characterizing the acute study effects and short-term safety profile of the drug in specific adult populations. The findings contribute to the overall body of knowledge regarding treatment approaches. Comparative effectiveness research against other available options is ongoing.

Key Studies & References

  1. Risperidone: Package Insert / Prescribing Information (FDA or EMA Label)

Frequently Asked Questions (FAQ)

Common questions about Respidone (FAQ)

Q: Does Respidone cause weight gain, and if so, how much is considered normal?

A: According to official product information, weight increased is a common adverse reaction observed in clinical trials. Because the amount of weight gain can vary between individuals, monitoring of weight by a healthcare professional is recommended.

Q: Are there any known long-term effects of using Respidone for several years?

A: Studies indicate that long-term use of this class of medicine carries a risk of developing a serious movement disorder known as tardive dyskinesia (TD). Extended elevation of prolactin levels, a hormone, may also lead to decreased bone density over time.

Q: Are there any common foods or beverages that should be avoided when using Respidone?

A: The medicine can generally be taken with or without food. If using the oral solution, official instructions state that it may be diluted in compatible non-alcoholic liquids, such as water or coffee. However, the solution is not compatible with tea or cola.

Q: Is it safe to consume caffeine while using Respidone?

A: The official administration guidelines for the oral solution mention that it can be diluted in coffee. While no explicit warnings regarding the consumption of caffeine are found in the core drug interaction regulatory databases, individuals should discuss any concerns with their prescribing professional.

Q: Do studies show Respidone affects blood sugar levels or diabetes risk?

A: Official product information states that this medicine is associated with metabolic changes, including hyperglycemia (high blood sugar). There is an officially recognized increased risk for diabetes mellitus with this class of medicine, and monitoring for these symptoms during treatment is recommended.

Q: Can Respidone affect driving ability or reaction time?

A: Regulatory documents state that this medicine has the potential to impair judgment, thinking, and motor skills. Patients should be aware of this potential impairment before operating hazardous machinery, including driving a car.

Q: What should people know about Respidone and heart health?

A: The medicine has been associated with certain cardiac effects, including orthostatic hypotension (a drop in blood pressure when standing up). It has also been associated with changes in the heart's electrical activity, such as QT prolongation. Due to these factors, patients with pre-existing cardiovascular disease may require careful monitoring.

Q: What common lab tests might be needed while taking Respidone?

A: Monitoring of metabolic parameters, such as blood glucose and weight, is often recommended. Additionally, complete blood counts (CBC) may also be performed for patients with a history of low white blood cell count.

Q: Does Respidone come with any specific regulatory box warnings?

A: The FDA label includes a Boxed Warning regarding the risk of increased mortality when used in elderly patients with dementia-related psychosis. This is a population for which the medicine is officially not approved for use.

Q: Are there any known withdrawal symptoms associated with stopping Respidone?

A: Official warnings state that neonates exposed to this medicine during the third trimester of pregnancy are at risk for withdrawal symptoms. For all patients, abrupt discontinuation is not recommended; cessation of the medicine involves a gradual reduction of dosage under the guidance of a healthcare professional.

Q: Is Respidone used for short-term or long-term management?

A: The medicine is formally indicated for the acute (short-term) and maintenance (long-term) treatment of schizophrenia. It is also indicated for the short-term and maintenance treatment of bipolar disorder.

Q: What are the general signs of an allergic reaction to Respidone?

A: The medicine is officially contraindicated in patients with known hypersensitivity (allergic reaction) to the active ingredient. Any signs of a severe allergic reaction, such as difficulty breathing or swelling of the face, lips, or tongue, warrant immediate consultation with a medical professional.

Q: What effect does Respidone have on appetite?

A: Studies and official information indicate that increased appetite has been reported as a common side effect in clinical trials.

Q: How long does it typically take for Respidone to start having a noticeable effect?

A: While acute benefits may occur sooner, official patient counseling information suggests that it may take several weeks or up to a few months (e.g., two to three months) for the optimal effects of the medicine to be established.

Q: What happens if a dose of Respidone is missed?

A: The official prescribing information contains specific guidance on managing a missed dose. These instructions vary based on whether the product is administered as an oral form or as the long-acting injectable suspension.

Q: Is Respidone described as a medication that should be taken for life?

A: This medicine is indicated for the maintenance (long-term) treatment of chronic conditions like schizophrenia. The duration of treatment is determined by the prescribing professional, and cessation of the medicine should not occur without professional guidance.

Q: How does Respidone interact with over-the-counter pain relievers like ibuprofen?

A: Review of the official drug interaction regulatory databases indicates that no specific interaction between this medicine and ibuprofen has been documented.

Q: Does Respidone work differently depending on the condition it is treating?

A: Regulatory information states that the medicine’s pharmacological action, which involves antagonizing both dopamine and serotonin receptors, is the same regardless of the condition for which it is prescribed.

Q: What is the half-life of Respidone?

A: According to the Clinical Pharmacology section of the official label, the mean elimination half-life of the active components (the medicine and its active metabolite) is approximately 20 hours.

Q: What is the general process for discontinuing Respidone?

A: Regulatory safety information states that abrupt discontinuation of this medicine is generally not recommended. If cessation of treatment is planned, it involves a process of gradually reducing the dosage under the guidance of a healthcare professional.

Q: What research exists about Respidone and cognitive function?

A: The official label includes a warning that the medicine has the potential to cause cognitive impairment. This potential effect is documented in the safety and warnings section.

Q: Can Respidone interact with herbal products like St. John's Wort?

A: Regulatory documents note that the herbal product St. John's Wort may interact with this medicine. It can significantly reduce the blood levels of the medicine, which may potentially make it less effective.

Q: Is there a generic version of Respidone available?

A: Yes, generic versions of the active ingredient, risperidone, are approved by the FDA and available in various formulations, including tablets, solution, and the long-acting injection.

Q: What is the typical reason for Respidone to be stopped?

A: In clinical trials, the most common reasons (adverse reactions) that led to participants discontinuing the medicine included somnolence, nausea, abdominal pain, dizziness, vomiting, agitation, and akathisia.

Q: Can Respidone cause changes in vision?

A: According to the official safety profile, blurred vision is a reported side effect of the medicine.

Q: Is it possible for Respidone to affect the menstrual cycle?

A: The medicine can increase the blood level of a hormone called prolactin (hyperprolactinemia). This may result in endocrine side effects such as absent, missed, or irregular menstrual periods in females.

Q: Is Respidone known to affect cholesterol levels?

A: Official product information notes that the medicine is associated with metabolic changes, including dyslipidemia (abnormal cholesterol or fat levels in the blood). Monitoring of these levels during treatment is recommended.

How should Respidone be stored and disposed of?

Official Storage and Disposal Instructions

Official regulatory labeling dictates strict conditions for storing and disposing of Respidone (Risperidone) based on the dosage form.

Dosage Form Required Storage Condition
Oral Forms (Tablets, Solution) Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F). Protect from light and moisture and do not freeze.
Injectable Kits Must be stored refrigerated (2 C to 8 C / 36 F to 46 F). Allow kits to sit at room temperature for the time specified in the label (e.g., 15–30 minutes) before use.

All medicine must be kept in its original container with the solution bottle tightly closed and stored out of the sight and reach of children. Orally disintegrating tablets must be used immediately upon removal from the blister.

Disposal of any unused or expired product must be done according to local regulations, such as drug take-back programs. Used injectable components, including needles, must be placed in a secure sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Respidone found in:

A-Z Index: